Metropolitan Life Insurance CO Ligand Pharmaceuticals Inc Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

57 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$68.64 - $89.2 $8,236 - $10,704	-120 Reduced 11.8%	897 $65,000
Q3 2023 Nov 14, 2023	BUY	$58.86 - $72.67 $6,180 - $7,630	105 Added 11.51%	1,017 $60,000
Q2 2023 Aug 10, 2023	BUY	$69.53 - $79.33 $5,075 - $5,791	73 Added 8.7%	912 $65,000
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $6,369 - $7,476	-97 Reduced 10.36%	839 $61,000
Q4 2022 Jun 14, 2023	BUY	$61.72 - $96.74 $5,986 - $9,383	97 Added 11.56%	936 $62.5 Million
Q4 2022 Mar 30, 2023	BUY	$61.72 - $96.74 $4,196 - $6,578	68 Added 7.83%	936 $62,000
Q4 2022 Feb 15, 2023	BUY	$61.72 - $96.74 $4,196 - $6,578	68 Added 7.83%	936 $62,000
Q3 2022 Jun 14, 2023	BUY	$0.01 - $107.56 $0 - $3,119	29 Added 3.46%	868 $74.7 Million
Q3 2022 Mar 30, 2023	SELL	$0.01 - $107.56 $1 - $13,767	-128 Reduced 12.85%	868 $74,000
Q3 2022 Nov 14, 2022	SELL	$0.01 - $107.56 $1 - $13,767	-128 Reduced 12.85%	868 $75,000
Q2 2022 Jun 20, 2023	BUY	$74.52 - $117.06 $11,699 - $18,378	157 Added 18.71%	996 $88,000
Q1 2022 Jun 20, 2023	BUY	$94.99 - $151.56 $14,913 - $23,794	157 Added 18.71%	996 $112,000
Q1 2022 Mar 30, 2023	SELL	$94.99 - $151.56 $290,004 - $462,712	-3,053 Reduced 75.4%	996 $112,000
Q1 2022 May 12, 2022	SELL	$94.99 - $151.56 $290,004 - $462,712	-3,053 Reduced 75.4%	996 $112,000
Q4 2021 Jun 21, 2023	BUY	$127.69 - $165.85 $409,884 - $532,378	3,210 Added 382.6%	4,049 $625,000
Q3 2021 Jun 21, 2023	BUY	$102.33 - $144.73 $328,479 - $464,583	3,210 Added 382.6%	4,049 $564,000
Q3 2021 Mar 30, 2023	SELL	$102.33 - $144.73 $286,728 - $405,533	-2,802 Reduced 40.9%	4,049 $564,000
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $286,728 - $405,533	-2,802 Reduced 40.9%	4,049 $564,000
Q2 2021 Jun 21, 2023	BUY	$113.03 - $155.64 $679,536 - $935,707	6,012 Added 716.57%	6,851 $898,000
Q2 2021 Mar 30, 2023	BUY	$113.03 - $155.64 $31,083 - $42,800	275 Added 4.18%	6,851 $898,000
Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $773,577 - $1.07 Million	6,844 Added 97771.43%	6,851 $899,000
Q1 2021 Jun 26, 2023	BUY	$99.52 - $215.83 $570,946 - $1.24 Million	5,737 Added 683.79%	6,576 $1 Billion
Q1 2021 Mar 30, 2023	SELL	$99.52 - $215.83 $44,485 - $96,476	-447 Reduced 6.36%	6,576 $1 Million
Q1 2021 May 14, 2021	SELL	$99.52 - $215.83 $698,232 - $1.51 Million	-7,016 Reduced 99.9%	7 $1 Million
Q4 2020 Jun 22, 2023	BUY	$80.55 - $106.05 $498,121 - $655,813	6,184 Added 737.07%	7,023 $698,000
Q4 2020 Mar 30, 2023	SELL	$80.55 - $106.05 $5,316 - $6,999	-66 Reduced 0.93%	7,023 $698,000
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $5,316 - $6,999	-66 Reduced 0.93%	7,023 $698,000
Q3 2020 Jun 26, 2023	BUY	$89.56 - $126.72 $559,750 - $792,000	6,250 Added 744.93%	7,089 $675,000
Q3 2020 Mar 30, 2023	SELL	$89.56 - $126.72 $13,254 - $18,754	-148 Reduced 2.05%	7,089 $675,000
Q3 2020 Nov 13, 2020	SELL	$89.56 - $126.72 $13,254 - $18,754	-148 Reduced 2.05%	7,089 $676,000
Q2 2020 Jun 26, 2023	BUY	$68.28 - $123.65 $436,855 - $791,112	6,398 Added 762.57%	7,237 $809,000
Q2 2020 Mar 30, 2023	SELL	$68.28 - $123.65 $134,989 - $244,456	-1,977 Reduced 21.46%	7,237 $809,000
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $134,989 - $244,456	-1,977 Reduced 21.46%	7,237 $809,000
Q1 2020 Jul 12, 2023	BUY	$63.37 - $107.88 $530,723 - $903,495	8,375 Added 998.21%	9,214 $670,000
Q1 2020 Mar 30, 2023	SELL	$63.37 - $107.88 $31,368 - $53,400	-495 Reduced 5.1%	9,214 $670,000
Q1 2020 May 15, 2020	SELL	$63.37 - $107.88 $31,368 - $53,400	-495 Reduced 5.1%	9,214 $670,000
Q4 2019 Jul 12, 2023	BUY	$96.94 - $113.59 $859,857 - $1.01 Million	8,870 Added 1057.21%	9,709 $1.01 Million
Q4 2019 Mar 30, 2023	SELL	$96.94 - $113.59 $112,741 - $132,105	-1,163 Reduced 10.7%	9,709 $1.01 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $112,741 - $132,105	-1,163 Reduced 10.7%	9,709 $1.01 Million
Q3 2019 Jul 12, 2023	BUY	$86.25 - $120.16 $865,346 - $1.21 Million	10,033 Added 1195.83%	10,872 $1.08 Million
Q3 2019 Mar 30, 2023	SELL	$86.25 - $120.16 $80,471 - $112,109	-933 Reduced 7.9%	10,872 $1.08 Million
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $80,471 - $112,109	-933 Reduced 7.9%	10,872 $1.08 Million
Q2 2019 Jul 12, 2023	BUY	$107.38 - $129.34 $1.18 Million - $1.42 Million	10,966 Added 1307.03%	11,805 $1.35 Million
Q2 2019 Mar 30, 2023	SELL	$107.38 - $129.34 $23,730 - $28,584	-221 Reduced 1.84%	11,805 $1.35 Million
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $23,730 - $28,584	-221 Reduced 1.84%	11,805 $1.35 Million
Q1 2019 Jul 13, 2023	BUY	$105.93 - $142.47 $1.19 Million - $1.59 Million	11,187 Added 1333.37%	12,026 $1.51 Million
Q1 2019 Mar 30, 2023	BUY	$105.93 - $142.47 $1.17 Million - $1.58 Million	11,090 Added 1184.83%	12,026 $1.51 Million
Q1 2019 May 16, 2019	BUY	$105.93 - $142.47 $631,660 - $849,548	5,963 Added 98.35%	12,026 $1.51 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $667,888 - $898,273	-6,305 Reduced 50.98%	6,063 $180,000
Q4 2018 Jul 13, 2023	BUY	$128.36 - $272.13 $1.48 Million - $3.14 Million	11,529 Added 1374.14%	12,368 $1.68 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $1.4 Million - $2.96 Million	10,889 Added 736.24%	12,368 $1.68 Million
Q3 2018 Jul 13, 2023	BUY	$211.18 - $274.49 $1.25 Million - $1.62 Million	5,913 Added 704.77%	6,752 $1.85 Billion
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $1.11 Million - $1.45 Million	-5,273 Reduced 78.1%	1,479 $406,000
Q2 2018 Aug 15, 2018	BUY	$150.77 - $207.98 $60,308 - $83,192	400 Added 6.3%	6,752 $0
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $33,132 - $43,646	-239 Reduced 3.63%	6,352 $0
Q4 2017 Feb 15, 2018	SELL	$128.36 - $147.04 $893,000 - $1.02 Million	-6,957 Reduced 51.35%	6,591 $903,000
Q2 2017 Aug 14, 2017	BUY	N/A	13,548	13,548 $1.65 Million

Others Institutions Holding LGND

# of Institutions

255

Shares Held

18.1M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.87B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account